DURECT (NASDAQ:DRRX) Issues Earnings Results, Beats Estimates By $0.05 EPS

DURECT (NASDAQ:DRRX) posted its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.05, Zacks reports. The firm had revenue of $2.17 million during the quarter, compared to the consensus estimate of $2.49 million. DURECT had a negative return on equity of 328.25% and a negative net margin of 279.77%. During the same quarter in the previous year, the business earned ($0.46) earnings per share.

DURECT Stock Performance

Shares of NASDAQ:DRRX traded down $0.10 during mid-day trading on Thursday, hitting $1.23. 40,550 shares of the company traded hands, compared to its average volume of 163,885. The firm’s 50 day simple moving average is $1.47 and its 200 day simple moving average is $1.19. The firm has a market cap of $38.17 million, a P/E ratio of -1.40 and a beta of 1.03. DURECT has a 52-week low of $0.47 and a 52-week high of $3.36.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on DRRX. HC Wainwright reiterated a “neutral” rating on shares of DURECT in a report on Wednesday, May 22nd. StockNews.com downgraded shares of DURECT from a “hold” rating to a “sell” rating in a research note on Thursday, August 8th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $21.00.

DURECT Company Profile

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.